Official-source baseline for Abeona Therapeutics using SEC submissions, SEC company facts, the FY2025 10-K, latest available 10-Q, filed FY2025 results release, filed launch update, 2026 proxy materials, and FDA product approval sources.
References
Sources used in this report
SEC issuer filing indexSEC submissions index for Abeona Therapeutics Inc.2026-05-13 · CIK, issuer identity, fiscal year end, latest filing selection, and confirmation that no Q1 FY2026 10-Q appeared in recent filings at cutoff.SEC company factsSEC XBRL company facts for Abeona Therapeutics Inc.2026-05-13 · Standardized cross-check of reported financial metrics.Annual reportAbeona Therapeutics FY2025 Form 10-K2026-03-17 · Business model, ZEVASKYN approval, RDEB context, clinical evidence, QTCs, payer coverage, manufacturing, pipeline, regulation, risks, and FY2025 financials.Quarterly reportAbeona Therapeutics Q3 FY2025 Form 10-Q2025-11-12 · Latest quarterly filing available at cutoff, cost structure, launch-transition costs, cash flow, debt, warrants, manufacturing issue, and J-code timing.Company results releaseAbeona FY2025 results release2026-03-17 · FY2025 revenue, first ZEVASKYN commercial patient treatment, PRV proceeds, cash, R&D, SG&A, and management launch commentary.Company launch updateAbeona March 2026 ZEVASKYN launch update2026-03-09 · Biopsy collections, early treatment cadence, commercial-payer policies, Medicaid coverage, permanent J-code, and ZEVASKYN safety information.Company governance updateAbeona April 2026 board appointment release2026-04-07 · Keith Goldan appointment as independent director and Audit Committee chair.Proxy statementAbeona 2026 DEF 14A proxy statement2026-04-27 · Board structure, independence, leadership separation, committees, risk oversight, insider policy, ownership, and compensation governance.FDA product approval pageFDA ZEVASKYN product page2025 · Regulator confirmation of STN 125807, proper name prademagene zamikeracel, trade name ZEVASKYN, and approved RDEB wound indication.FDA approvals tableFDA CBER RMAT approvals table2025 · Regulator confirmation of BLA 125807, applicant, approval date, product name, and RDEB use.